Privately-owned Akarna Therapeutics Ltd has raised $15 million in a Series B financing round to advance a preclinical drug for non-alcoholic steatohepatitis (NASH), a fatty-liver disease that is associated with both diabetes and obesity. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
